NEW YORK, NY / ACCESSWIRE / February 14, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Talkspace, Inc. f/k/a Hudson Executive Investment Corporation (NASDAQ:TALK)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/talkspace-inc-f-k-a-hudson-executive-investment-corporation-loss-submission-form?prid=23682&wire=1
Lead Plaintiff Deadline: March 8, 2022
This lawsuit is on behalf of: (a) all persons or entities that purchased or otherwise acquired Talkspace securities between June 11, 2020 and November 15, 2021, both dates inclusive, and/or (b) all holders of Talkspace common stock as of the record date for the special meeting of shareholders held on June 17, 2021.
Allegations against TALK include that: (i) Hudson Executive Investment Corporation (“HEIC”) had overstated its competitive advantage and due diligence capabilities with respect to identifying and effectuating a merger with target companies; (ii) HEIC had conducted inadequate due diligence into then-private, pre-Merger Talkspace, or else ignored and/or failed to disclose multiple red flags concerning then-private, pre-Merger Talkspace’s business and operations; (iii) Talkspace was experiencing significantly increased online advertising costs in its B2C business since the beginning of 2021; (iv) Talkspace was experiencing lower conversion rates in its online advertising in its business-to-consumer (“B2C”) business; (v) as a result of (iii) and (iv) above, Talkspace was experiencing increased customer acquisition costs and more tepid B2C demand than represented to investors; (vi) as a result of (iii)-(v) above, Talkspace was suffering from ballooning customer acquisition costs and worsening growth and gross margin trends; (vii) Talkspace had overvalued its accounts receivables from certain of its health plan clients in its B2B business, which amounts required adjustment downward; and (viii) as a result of (iii)-(vii) above, Talkspace’s 2021 financial guidance was not achievable and lacked any reasonable basis in fact.
Biogen Inc. (NASDAQ:BIIB)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/biogen-inc-loss-submission-form-2?prid=23682&wire=1
Lead Plaintiff Deadline: April 8, 2022
Class Period: June 7, 2021 – January 11, 2022
Allegations against BIIB include that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration (“FDA”) that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer’s disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer’s patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019; and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and that side-effects were dangerous and serious.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?prid=23682&wire=1
Lead Plaintiff Deadline: April 11, 2022
Class Period: May 28, 2021 – November 26, 2021
Allegations against FENC include that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/688651/SHAREHOLDER-ALERT-TALK-BIIB-FENC-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines